肿瘤源性IL-35促进肿瘤血管生成的研究进展

于佳兴; 李增勋; 黄崇标

doi:10.12354/j.issn.1000-8179.2021.20210155

肿瘤源性IL-35促进肿瘤血管生成的研究进展

doi: 10.12354/j.issn.1000-8179.2021.20210155

天津医科大学肿瘤医院胰腺肿瘤科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室（天津市 300060）

详细信息

作者简介:
于佳兴：专业方向为肿瘤学研究

通讯作者:
黄崇标　chhuang@tmu.edu.cn

计量
- 文章访问数: 207
- HTML全文浏览量: 71
- PDF下载量: 29
- 被引次数: 0
出版历程
- 收稿日期: 2021-01-22
- 网络出版日期: 2021-09-14
- 刊出日期: 2021-09-14

Research progress on the roles of IL-35 in tumor angiogenesis

Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China

More Information

Corresponding author: Chongbiao Huang; E-mail: chhuang@tmu.edu.cn

摘要

摘要: 白细胞介素-35（interleukin-35，IL-35）是IL-12家族中新发现的异二聚体细胞因子，其与TGF-β、IL-10被认为是三种最重要的免疫抑制因子。IL-35广泛表达于多种免疫细胞及肿瘤细胞。近年来越来越多的研究表明，IL-35在恶性肿瘤中不仅发挥着免疫抑制作用，同时在肿瘤细胞增殖、凋亡、侵袭迁移、血管生成等恶性行为中发挥重要作用。肿瘤血管生成是实体肿瘤发生发展中不可或缺的环节，本文对IL-35在肿瘤血管生成中的作用进行分析总结，以供临床和基础研究参考。
- IL-35 /
- 肿瘤血管生成 /
- 恶性肿瘤
Abstract: Interleukin-35 (IL-35) is a newly discovered heterodimeric cytokine that belongs to the IL-12 family. IL-35 is one of the three most important immunosuppressive factors, along with transforming growth factor-β (TGF-β) and IL-10. IL-35 is expressed in various immune and tumor cells. In recent years, several studies have shown that in addition to having an immunosuppressive effect on malignant tumors, IL-35 plays an important role in tumor cell proliferation, apoptosis, invasion and migration, and angiogenesis. Tumor angiogenesis is indispensable to the development of solid tumors. This article analyzes and summarizes the role of IL-35 in tumor angiogenesis, acting as a reference for clinical and basic research.
- interleukin-35 (IL-35) /
- tumor angiogenesis /
- malignant tumor

HTML全文

图 1 IL-35受体以及信号通路^[1]

下载: 全尺寸图片幻灯片

图 2 IL-35促进胰腺癌血管生成模式^[22]

下载: 全尺寸图片幻灯片

参考文献(28)

[1]	Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J]. Nature, 2007, 450(7169):566-569. doi: 10.1038/nature06306
[2]	Haller S, Duval A, Migliorini R, et al. Interleukin-35-producing CD8α⁺ dendritic cells acquire a tolerogenic state and regulate T cell function[J]. Front Immunol, 2017, 8:98.
[3]	Tsuda M, Zhang W, Yang G X, et al. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFbeta receptor type Ⅱ mice[J]. Hepatology, 2013, 57(2):806-816. doi: 10.1002/hep.25829
[4]	Kang M, Choi J K, Jittayasothorn Y, et al. Interleukin 35-producing exosomes suppress neuroinflammation and autoimmune uveitis[J]. Front Immunol, 2020, 11:1051.
[5]	Alsharabasy AM, Glynn SA, Pandit A. The role of extracellular matrix in tumour angiogenesis: the throne has NOx servants[J]. Biochem Soc Trans, 2020, 48(6):2539-2555. doi: 10.1042/BST20200208
[6]	Riabov V, Gudima A, Wang N, et al. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis[J]. Front Physiol, 2014, 5:75.
[7]	Bikfalvi A. Tumor angiogenesis[J]. Bull Cancer, 2003, 90(5):449-458.
[8]	Song YS, Kim MJ, Sun HJ, et al. Aberrant thyroid-stimulating hormone receptor signaling increases VEGF-A and CXCL8 secretion of thyroid cancer cells, contributing to angiogenesis and tumor growth[J]. Clin Cancer Res, 2019, 25(1):414-425. doi: 10.1158/1078-0432.CCR-18-0663
[9]	Guo P, Wang Y, Dai C, et al. Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/beta-catenin-induced FGF18 expression in hepatocellular carcinoma[J]. Oncogene, 2018, 37(9):1220-1236.
[10]	Safina A, Vandette E, Bakin AV. ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells[J]. Oncogene, 2007, 26(17):2407-2422. doi: 10.1038/sj.onc.1210046
[11]	Rahma OE, Hodi FS. The Intersection between tumor angiogenesis and immune suppression[J]. Clin Cancer Res, 2019, 25(18):5449-5457. doi: 10.1158/1078-0432.CCR-18-1543
[12]	Mastrella G, Hou M, Li M, et al. Targeting APLN/APLNR improves antiangiogenic efficiency and blunts proinvasive side effects of VEGFA/VEGFR2 blockade in glioblastoma[J]. Cancer Res, 2019, 79(9):2298-2313.
[13]	Tanaka I, Morise M, Miyazawa A, et al. Potential benefits of bevacizumab combined with platinum-based chemotherapy in advanced non-small-cell lung cancer patients with EGFR mutation[J]. Clin Lung Cancer, 2020, 21(3):273-280. doi: 10.1016/j.cllc.2020.01.011
[14]	Lee CC, Lin JC, Hwang WL, et al. Macrophage-secreted interleukin-35 regulates cancer cell plasticity to facilitate metastatic colonization[J]. Nat Commun, 2018, 9(1):3763. doi: 10.1038/s41467-018-06268-0
[15]	Pylayeva-Gupta Y, Das S, Handler JS, et al. IL35-producing B cells promote the development of pancreatic neoplasia[J]. Cancer Discov, 2016, 6(3):247-255. doi: 10.1158/2159-8290.CD-15-0843
[16]	Hao S, Chen X, Wang F, et al. Breast cancer cell-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells[J]. Carcinogenesis, 2018, 39(12):1488-1496.
[17]	Huang C, Li N, Li Z, et al. Tumour-derived interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression[J]. Nat Commun, 2017, 8:14035.
[18]	Wang Z, Liu JQ, Liu Z, et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis[J]. J Immunol, 2013, 190(5):2415-2423.
[19]	Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin[J]. Proc Natl Acad Sci U S A, 1997, 94(22):12041-12046.
[20]	Kleeff J, Korc M, Apte M, et al. Pancreatic cancer[J]. Nat Rev Dis Primers, 2016, 2:16022. doi: 10.1038/nrdp.2016.22
[21]	Jin P, Ren H, Sun W, et al. Circulating IL-35 in pancreatic ductal adenocarcinoma patients[J]. Hum Immunol, 2014, 75(1):29-33. doi: 10.1016/j.humimm.2013.09.018
[22]	Huang C, Li Z, Li N, et al. Interleukin 35 Expression correlates with microvessel density in pancreatic ductal adenocarcinoma, recruits monocytes, and promotes growth and angiogenesis of xenograft tumors in mice[J]. Gastroenterology, 2018, 154(3):675-688. doi: 10.1053/j.gastro.2017.09.039
[23]	Li X, Niu N, Sun J, et al. IL35 predicts prognosis in gastric cancer and is associated with angiogenesis by altering TIMP1, PAI1 and IGFBP1[J]. FEBS Open Bio, 2020, 10(12):2687-2701. doi: 10.1002/2211-5463.13005
[24]	Jiang S, Li Y, Lin T, et al. IL-35 inhibits angiogenesis through VEGF/Ang2/Tie2 pathway in rheumatoid arthritis[J]. Cell Physiol Biochem, 2016, 40(5):1105-1116. doi: 10.1159/000453165
[25]	Wu S, Li Y, Yao L, et al. Interleukin-35 inhibits angiogenesis through STAT1 signalling in rheumatoid synoviocytes[J]. Clin Exp Rheumatol, 2018, 36(2):223-227.
[26]	Liu S, Li Y, Xia L, et al. IL-35 prevent bone loss through promotion of bone formation and angiogenesis in rheumatoid arthritis[J]. Clin Exp Rheumatol, 2019, 37(5):820-825.
[27]	Turnis ME, Sawant DV, Szymczak-Workman AL, et al. Interleukin-35 limits anti-tumor immunity[J]. Immunity, 2016, 44(2):316-329. doi: 10.1016/j.immuni.2016.01.013
[28]	Liao KL, Bai XF, Friedman A. Mathematical modeling of Interleukin-35 promoting tumor growth and angiogenesis[J]. PLoS One, 2014, 9(10):e110126. doi: 10.1371/journal.pone.0110126